Jan 3 (Reuters) - Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.19 USD | -3.35% | -1.04% | +49.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.03% | 1.88B | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.35% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios' blood disorder drug meets goals of late-stage study